#retatrutide

#retatrutide

The next generation of GLP-1 weight loss drugs has taken another step forward to U.S. Food and Drug Administration (FDA) approval. In new clinical trial results from pharmaceutical company Eli Lilly, a weekly injection of retatrutide for 80 weeks helped people lose about 30 percent of their body weightabout 85 pounds on averageaccording to a statement from the company. That puts retatrutide essentially on a par with bariatric surgery, says Daniel Drucker, a university professor of medicine at the University of Toronto, who has previously consulted for Eli Lilly but was not involved in the trial.

Decreased risk of Alzheimer's and dementia, satiety, lipid management, et cetera. I have been injecting a teeny tiny microdose of something called Retatrutide on Monday, Wednesday and Friday mornings. That's a triple hormone receptor agonist. It's a peptide. It targets GLP1, it targets something called GIP, and it targets glucagon. So it has three different ways that it suppresses hunger and helps out with appetite management along with all these other effects.